Form D · Biotechnology
Trace Biosciences Inc.
Beaverton, OR · CIK 0002147501
Offering snapshot reported Aug 12, 2026 · SEC filing
- Reported sold
- $8.33M Offering amount: $16.2M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 28, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2026 | Initial | $8,334,499 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593916
Source: Form D, filed Aug 12, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Connor Barth | Director, Executive |
| Summer Gibbs | Director, Executive |
| Jonathan Sorger | Director |
| Lei Wang | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1800 Nw 167 Th Pl Ste 160
Beaverton, OR, 97006
Phone: (971) 202-0545
Beaverton, OR, 97006
Phone: (971) 202-0545